Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Remdesivir vs Chloroquine in Covid 19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04345419
Recruitment Status : Recruiting
First Posted : April 14, 2020
Last Update Posted : August 18, 2020
Sponsor:
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
COVID 19 treatment using Chloroquine, Remedesvir.

Condition or disease Intervention/treatment Phase
COVID Drug: Chloroquine or hydroxychloroquine Drug: Remdesivir Phase 2 Phase 3

Detailed Description:
COVID 19 treatment using Chloroquine or Remedesvir. Which drug is more effective?

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Remdesivir in COVID 19 Treatment: A Randomised Trial
Actual Study Start Date : June 16, 2020
Estimated Primary Completion Date : December 2029
Estimated Study Completion Date : December 2029


Arm Intervention/treatment
Experimental: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine tablets
Drug: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine pills
Other Name: Alexoquine or hydroquine

Experimental: Remdesivir
Remdesivir as antiviral treatment
Drug: Remdesivir
Remdesivir as antiviral drug




Primary Outcome Measures :
  1. Number of patients with improvement or mortality [ Time Frame: 6 months ]
    the estimated number of patients with improvement or mortality



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COVID 19 patients

Exclusion Criteria:

  • allergy or contraindication to the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04345419


Contacts
Layout table for location contacts
Contact: Sherief Abd-Elsalam +201147773440 sheriefabdelsalam@yahoo.com

Locations
Layout table for location information
Egypt
Tanta university hospital, Assuit University, Ainshams University Recruiting
Tanta, Egypt
Contact: Sherief Abd-Elsalam    00201000040794    Sherif_tropical@yahoo.com   
Sponsors and Collaborators
Tanta University
Investigators
Layout table for investigator information
Principal Investigator: Sherief Abd-Elsalam, ass. prof. Tanta University Faculty of medicine
Study Director: Eslam Saber, ass. lect Tanta University Faculty of medicine
Study Chair: Mai Khalaf, ass. lect. Tanta University Faculty of medicine
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, assistant professor of tropical medicine and infectious diseases, Tanta University
ClinicalTrials.gov Identifier: NCT04345419    
Other Study ID Numbers: COVID 19 treatment
First Posted: April 14, 2020    Key Record Dates
Last Update Posted: August 18, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydroxychloroquine
Chloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents
Amebicides